A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

Also called NCT02634151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 105 participants (enrolled count) (from the registry)
Sponsor
NeuroBo Pharmaceuticals Inc. (from the registry)
Registry
  • NCT NCT02634151
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02634151. Randomized; quadruple masking; primary purpose treatment. Start 2016-11 (registry gives no type); primary completion 2017-06 (actual). Results posted on 2020-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins
Acronym
ROYAL-1
Condition
Hypercholesteremia
Intervention (Drug)
Gemcabene
Intervention (Drug)
Placebo
Lead sponsor
NeuroBo Pharmaceuticals Inc. (class: industry)

Record details

Record id
cardio:ct-nct02634151
Content hash
7a63dc1089e475d5f5a4b80b7b4eda29a256e08a89ed0610f7ef1b4758266c89